Abstract:Abstract Background Approximately half of patients with IBD in clinical remission (CR) flare within 12 months of withdrawing anti-TNF therapy. However, the outcomes of vedolizumab (VDZ) or ustekinumab (UST) cessation in terms of CR in routine practice are unknown. There is a need for more data to establish the relapse rates following treatment cessation. Methods This was a retrospective observational multicenter study. We included adult IBD patients who had withdrawn from either VDZ or UST after achieving CR and had available follow-up data for one year following treatment discontinuation or until relapse occurred. The control arm comprised patients discontinuing anti-TNFs after achieving CR. The primary objectives of this study are to assess the clinical relapse rates after discontinuing VDZ or UST and to identify potential predictors of sustained remission and relapse after therapy discontinuation. Results A total of 133 patients were included (48.1% Crohn’s disease and 51.9% ulcerative colitis). Sixty out of the 133 (45%) patients discontinued anti-TNF, 54 (40%) VDZ and 19 (15%) UST. All patients were in CR prior to drug discontinuation. The most common cause for drug discontinuations was patients’ preferences (80%) followed by cost and administrative issues. Duration of remission before drug discontinuation was 11 (IQR 7.5-10), 8.5 (6-12.2), and 12 (8-27) months, for anti-TNF, VDZ, and UST, respectively. The median follow-up duration was 14 months (5.5-20), with an overall relapse rate of 78.9% (105/133). Relapse rates in each cohort were 71.6%, 83.3%, and 89.4%, respectively, p=0.5. The median time to relapse was 10 months (3-9), 9 (6-16.5), and 8 (5-16.5), respectively. There was no significant difference in the relapse rates between the different drugs (anti-TNF vs VDZ, anti-TNF vs UST, and VDZ vs UST, (hazard ratio, HR 1.2, confidence interval, CI 95% 0.2-1.8; P = 0.35), HR 1.2, CI 95% 0.9-1.6; p=0.13, HR 1.2, CI 95% 0.6-2.1; P=0.5, respectively). Predictors of relapse after drug withdrawal were a short treatment period (HR 0.98, CI 95% 0.96-0.99; P = 0.04), shorter remission period (HR 0.9, CI 95% 0.95-0.99, P =0.03), multiple prior biologics (HR 1.2, CI 95% 1.04-1.44, P= 0.013), perianal disease (HR 5.5, CI 95% 1.6-1.8, P=0,006) and lower hemoglobin level (HR 1.95, CI 95% 1.1-3.1, P= 0.008). The following factors were not associated with an increased risk of relapse: IBD type, disease phenotype, extraintestinal manifestations, active smoking status, prior IBD-related surgery, elevated CRP or calprotectin, and endoscopic or radiologic signs of active disease. Conclusion In IBD patients that discontinue biologics after achieving clinical remission, relapse rates following withdrawal of VDZ and UST are comparable with those of anti-TNF.

Anti-TNF Withdrawal in Inflammatory Bowel Disease with Endoscopic Healing and the Risk of Relapse

Long-term Clinical Outcomes after the Discontinuation of Anti-Tnf Agents in Patients with Inflammatory Bowel Disease: a Meta-Analysis.

P731 Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A single-center experience

DOP70 Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective study

The Relapse Rate of Inflammatory Bowel Disease (IBD) in Patients Who Discontinue Anti-TNF Therapy: A Systematic Review and Meta-Analysis

Discontinuation of Biological Treatments in Inflammatory Bowel Disease

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

Design How / When Concomitant IMMs [ n ( % ) ] Fecal Calprotectin ( μ g / g ) Blood In fl ammatory Markers Clinical Studies Predictors

P769 Impact of discontinuation of anti-TNF therapy: A long term follow-up data of risks and predictors relapse in a large Indian cohort

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice

Tu1321 Systematic Review with Meta-Analysis of Prospective Studies: Anti-TNFs for Prevention of Postoperative Crohn's Disease Recurrence

P755 Long-term need for restart of biologics after withdrawal in patients with Inflammatory Bowel Disease in mucosal healing

P510 Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease. The VEDUST-EXIT study

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing

P546 Endoscopic findings related to the long-term response to anti-TNF-α antibody treatment in patients with Crohn's disease

Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

DOP066. Impaired Mucosal Permeability Underlies Ongoing Irritable Bowel Syndrome-Like Symptoms, in Patients with Inflammatory Bowel Disease Who Have Achieved Mucosal Healing

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

Outcomes of Perianal Fistulising Crohn's Disease Following Anti-TNFα Treatment Discontinuation

Comparison of modified gunsight suture technique and traditional interrupted suture in enterostomy closure